Biovica, active in blood-based cancer monitoring, has signed a new Master Service Agreement (MSA) – along with an initial Work Order of ~800 kSEK – with a Tier-1 US-based biopharmaceutical company. The new customer, a global leader in oncology drug development, becomes the fifth Tier-1 US biopharma company to join Biovica’s Pharma Services customer base.
The agreement covers testing of Phase 1 clinical trial samples in support of the development of next-generation CDK4/6 inhibitors and is a pilot study with DiviTum® TKa.
“This marks a milestone in our growing customer base, highlighting the increasing relevance of Biovica’s TKa biomarker assay in advanced cancer therapy development. It demonstrates the strong and growing recognition of the value our assay brings to the development of next-generation oncology treatments that ultimately benefit cancer patients.,” said Anders Rylander, CEO of Biovica.